David Stassen
Co-Founding Managing Director @ Split Rock Partners
San Francisco, United States
David Stassen is a Series A investor at Split Rock Partners in San Francisco focused on Health Care and Medical. David Stassen is the Co-Founding Managing Director of Split Rock Partners & he attended University of St. Thomas in 1969.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries David Stassen invests in
Stages David Stassen invests in
Countries David Stassen invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (30%)
- Medical 2 (20%)
- Biotechnology 2 (20%)
- Medical Device 2 (20%)
- Information Technology 1 (10%)
Stage
- Series A 2 (20%)
- Series B 2 (20%)
- Series C 2 (20%)
- Series D 2 (20%)
- Seed 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nuvaira
|
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $79M / Series E / Feb 11, 2019 | |
Zyga Technology
|
Zyga Technology is a surgical solutions provider developing & commercializing medical devices for treating spine problems. In addition to the SImmetry Sacroiliac Joint Fusion System, the company is also developing the Glyder Facet Restoration Device. Zyga has put together a team of engineers, marketing personnel, and management with significantexperience developing medical devices for the spine industry.Zyga Technology was founded in 2008 and is headquartered in Minnesota, USA. | $2M / Series D / Sep 25, 2014 | |
|
Nuvaira
|
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $42M / Series D / Apr 03, 2014 | |
|
Nuvaira
|
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $10M / Series C / Feb 08, 2013 | |
|
Nuvaira
|
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $10.6M / Series B / Sep 20, 2012 | |
|
Zyga Technology
|
Zyga Technology is a surgical solutions provider developing & commercializing medical devices for treating spine problems. In addition to the SImmetry Sacroiliac Joint Fusion System, the company is also developing the Glyder Facet Restoration Device. Zyga has put together a team of engineers, marketing personnel, and management with significantexperience developing medical devices for the spine industry.Zyga Technology was founded in 2008 and is headquartered in Minnesota, USA. | Series C / May 16, 2012 | |
|
Nuvaira
|
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | Series A / Sep 29, 2010 | |
Nexis Vision
|
Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC. | Series B / Jun 18, 2009 | |
|
Nexis Vision
|
Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC. | Series A / Jan 07, 2008 | |
|
Nuvaira
|
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | Seed |
Co-Investors
About Split Rock Partners
Split Rock Partners invests in emerging healthcare, software and Internet services companies in the Upper Midwest and West Coast. They are an early-stage venture capital firm that was founded in June 2004 by the former healthcare and software investment teams of St. Paul Venture Capital (SPVC). The Split Rock team managed over $1 billion of venturecapital during our tenure at SPVC, and continues to manage the SPVC healthcare and software portfolio. In May of 2008, they raised $300 million in the second Split Rock Partners fund, the successor to their inaugural $275 million fund raised in April 2005.The Split Rock team believes that it takes great people to translate promising ideas into compelling businesses. They are grounded in a fundamental respect for entrepreneurs and the rare combination of elements required when pioneering new markets. They start by looking for entrepreneurs with the passion, vision, and skills to build leading companies. They then work with entrepreneurs collaboratively, building partnerships based on integrity and mutual respect. The Split Rock team complements management expertise with over 80 years of venture investing and entrepreneurial management experience. They are proud of the strong relationships they have built with talented entrepreneurs and co-investors throughout their history and look forward to building on that tradition.
Split Rock Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
David Stassen
Co-Founding Managing Director
|
|||
Jim Simons
Co-Founding Managing Director
|
|||
Michael Gorman
Co-Founding Managing Director
|
|||
Steven Schwen
CFO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David Stassen invest in?
David Stassen invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact David Stassen?
Public channels for David Stassen include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did David Stassen last invest?
The most recent investment recorded for David Stassen closed in Feb 2019. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
